These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 1794028)

  • 21. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
    Pontiroli AE; Pajetta E; Scaglia L; Rubinacci A; Resmini G; Arrigoni M; Pozza G
    Aging (Milano); 1994 Dec; 6(6):459-63. PubMed ID: 7748920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of Paget's disease of bone using synthetic salmon calcitonin administered intranasally].
    Reginster JY; Albert A; Franchimont P
    Rev Med Liege; 1986 Jan; 41(1):13-8. PubMed ID: 3952394
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients.
    Reginster JY; Albert A; Franchimont P
    Calcif Tissue Int; 1985 Dec; 37(6):577-80. PubMed ID: 3937575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Paget's disease of bone with salmon calcitonin.
    Manderlier T; Fuss M; Brauman J; Orloff S; Bergans A; Corvilain J
    Acta Clin Belg; 1976; 31(6):329-38. PubMed ID: 1035459
    [No Abstract]   [Full Text] [Related]  

  • 26. Long- and short-term side effects and safety of calcitonin in man: a prospective study.
    Wimalawansa SJ
    Calcif Tissue Int; 1993 Feb; 52(2):90-3. PubMed ID: 8443697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
    Kopaliani M
    Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
    Shai F; Baker RK; Wallach S
    J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.
    Oreopoulos DG; Husdan H; Harrison J; Meema HE; McNeill KG; Murray TM; Ogilvie R; Rapoport A
    Can Med Assoc J; 1977 Apr; 116(8):851-5. PubMed ID: 856428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of drugs for Paget's disease of bone.
    Reginster JY; Lecart MP
    Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Variations in parathormone serum levels during treatment of Paget's disease with calcitonin of human or salmon origin (author's transl)].
    Heynen G; Franchimont P; Gaspar S; Gysen P; Kanis JA
    Ann Endocrinol (Paris); 1981; 42(3):265-75. PubMed ID: 7316460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcitonin as a drug.
    Deftos LJ; First BP
    Ann Intern Med; 1981 Aug; 95(2):192-7. PubMed ID: 7258871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial: salmon calcitonin in the treatment of Paget disease.
    Goldsmith RS
    JAMA; 1975 Jun; 232(11):1156-7. PubMed ID: 1173622
    [No Abstract]   [Full Text] [Related]  

  • 36. Metabolic effects of synthetic salmon calcitonin in Paget's disease of bone.
    Avramides A; Baker RK; Wallach S
    Metabolism; 1974 Nov; 23(11):1037-46. PubMed ID: 4472557
    [No Abstract]   [Full Text] [Related]  

  • 37. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.
    Singer FR; Fredericks RS; Minkin C
    Arthritis Rheum; 1980 Oct; 23(10):1148-54. PubMed ID: 7000081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On the treatment of the osteodystrophia deformans (Paget's disease) with synthetic salmon calcitonin (author's transl)].
    Trzenschik K; Schmidt UJ; Abendroth K; Ansorg H; Graner H; Lindenhayn K; Schramm G; Kalbe I
    Z Alternsforsch; 1978; 33(5):441-51. PubMed ID: 570764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and therapeutic use of calcitonin.
    Stevenson JC; Evans IM
    Drugs; 1981 Apr; 21(4):257-72. PubMed ID: 7014170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin.
    Rojanasathit S; Rosenberg E; Haddad JG
    Lancet; 1974 Dec; 2(7894):1412-5. PubMed ID: 4140329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.